###BASE_URL###
2007-04-16 | permalink
Legislation allowing generic versions of medications made using biotechnology could result in dangerous treatments, a drugmaker and a senior U.S. senator said at a hearing yesterday. The proposed bill is flawed because it could permit companies to skip human trials before medications are approved, a representative of Johnson & Johnson, which makes biotech drugs, and Sen. Orrin Hatch, R-Utah, said at a hearing of the Senate health committee.
2007-04-16 | permalink
Legislation allowing generic versions of medications made using biotechnology could result in dangerous treatments, a drugmaker and a senior U.S. senator said at a hearing yesterday. The proposed bill is flawed because it could permit companies to skip human trials before medications are approved, a representative of Johnson & Johnson, which makes biotech drugs, and Sen. Orrin Hatch, R-Utah, said at a hearing of the Senate health committee.
GENET-news is providing a daily news service on a range of topics regarding genetic engineering. We are screening the worldwide English news, press releases and other publications to provide you with a strategic selection of information. GENET-news enables you to stay informed about all aspects of the global controversy around GE technologies and GE organisms. You can subscribe by email.
The GENET-forum list provides you with additional background information and more voluminous reports. It is only open for GENET members. Please contact the coordinator for membership and subscription.